Nicotinamide Phosphoribosyltransferase – Pipeline Review, H2 2020

Global Markets Direct’s, ‘Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) – Pipeline Review, H2 2020’, provides in depth analysis on Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Infectious Disease, Toxicology, Cardiovascular, Central Nervous System and Respirator under development targeting Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12)

– The report reviews Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics and enlists all their major and minor projects

– The report assesses Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AbbVie Inc

Aqualung Therapeutics Corp

Aurigene Discovery Technologies Ltd

Calico LLC

Eli Lilly and Co

Genentech USA Inc

Karyopharm Therapeutics Inc

OncoTartis Inc

Tianjin Hemay Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC

2.4.2.12) - Overview

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC

2.4.2.12) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC

2.4.2.12) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC

2.4.2.12) - Companies Involved in Therapeutics Development

AbbVie Inc

Aqualung Therapeutics Corp

Aurigene Discovery Technologies Ltd

Calico LLC

Eli Lilly and Co

Genentech USA Inc

Karyopharm Therapeutics Inc

OncoTartis Inc

Tianjin Hemay Pharmaceutical Co Ltd

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC

2.4.2.12) - Drug Profiles

ALT-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AU-4869 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

enamptcumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GNE-617 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hemay-088 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KPT-9274 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LSN-3154567 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OT-82 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P7-C3A20 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NAMPT for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STF-118804 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC

2.4.2.12) - Dormant Products

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC

2.4.2.12) - Discontinued Products

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC

2.4.2.12) - Product Development Milestones

Featured News & Press Releases

Oct 19, 2020: Researchers discover neuroprotective treatment for chronic traumatic brain injury

Jun 02, 2020: Aqualung Therapeutics receives A $2.3 million National Institute Of Health (NIH) Fast-Track award to develop a novel therapeutic antibody for patients with radiation-induced lung injury

May 27, 2020: Aqualung Therapeutics receives NIH approval to advance to IND-enabling studies via the STTR Fastrack Phase II award for development of a novel anti-inflammatory therapeutic antibody for ARDS and the critically ill

Apr 13, 2020: Antengene announces dosing of first patient in the ATG-019 (KPT-9274) phase 1 trial, a first-in-class dual inhibitor, for advanced solid tumors and non-hodgkin's lymphoma

Mar 18, 2020: Aqualung Therapeutics advances its investigational monoclonal antibody into IND-enabling studies of Acute Respiratory Distress Syndrome (ARDS) And Ventilator-Induced Lung Injury (VILI)

Jan 16, 2020: International research collaboration reveals promising drug candidate for treatment of blood cancers

Dec 05, 2019: Aqualung Therapeutics to present new data at Biotech Showcase Investor Conference

Aug 20, 2019: Aqualung Therapeutics receives $225 thousand dollar National Institute of Health (NIH) grant to establish biomarker panel for patients with acute respiratory distress syndrome

Aug 13, 2019: Aqualung Therapeutics submits patent application to USPTO

Aug 06, 2019: Aqualung Therapeutics filed patent for eNamptor

Jul 20, 2019: Aqualung Therapeutics provides update on eNamptor

Jul 13, 2019: Aqualung Therapeutics submits $3 million Department of Defense grant for eNamptor

Jun 05, 2019: Aqualung Therapeutics receives a $1.7 Million National Institute Of Health (NIH) Fastrack Award To develop an novel immune-based therapeutic antibody for critically ill patients with acute lung injury

Jun 04, 2019: Aqualung Therapeutics Corporation receives A $1.7 million National Institute of Health (NIH) fastrack award to develop an novel immune-based therapeutic antibody for critically Ill patients with acute lung injury

Mar 19, 2018: Karyopharm to Present Preclinical Data on KPT-9274 at the American Association for Cancer Research 2018 Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Indications, H2 2020

Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020

Number of Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020 (Contd..1), H2 2020

Products under Development by Companies, H2 2020 (Contd..2), H2 2020

Number of Products under Investigation by Universities/Institutes, H2 2020

Products under Investigation by Universities/Institutes, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Pipeline by AbbVie Inc, H2 2020

Pipeline by Aqualung Therapeutics Corp, H2 2020

Pipeline by Aurigene Discovery Technologies Ltd, H2 2020

Pipeline by Calico LLC, H2 2020

Pipeline by Eli Lilly and Co, H2 2020

Pipeline by Genentech USA Inc, H2 2020

Pipeline by Karyopharm Therapeutics Inc, H2 2020

Pipeline by OncoTartis Inc, H2 2020

Pipeline by Tianjin Hemay Pharmaceutical Co Ltd, H2 2020

Dormant Projects, H2 2020

Discontinued Products, H2 2020

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Top 10 Indications, H2 2020

Number of Products by Mechanism of Actions, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Molecule Types, H2 2020

Number of Products by Stage and Molecule Types, H2 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports